Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Carol Fabian, MD, University of Kansas Medical Center Identifier:
First received: March 6, 2003
Last updated: February 13, 2017
Last verified: February 2017

RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women.

PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer in premenopausal women who are at risk of developing cancer.

Condition Intervention Phase
Breast Cancer
Drug: celecoxib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer

Resource links provided by NLM:

Further study details as provided by University of Kansas Medical Center:

Enrollment: 110
Study Start Date: January 2003
Study Completion Date: July 2013
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Celecoxib 400 mg bid
Celecoxib 400 mg bid
Drug: celecoxib
Celecoxib daily for 12 months
Other Name: Celebrex

Detailed Description:


  • Determine the change in proliferation in benign breast epithelial cells as measured by Ki-67/MIB-1 in premenopausal women at high risk for estrogen receptor-negative breast cancer treated with celecoxib.
  • Determine the feasibility of this regimen by dropout rate of these patients during 12 months of treatment and compliance.
  • Determine the proportion of these women likely to express cyclooxygenase-2 protein (COX-2) in at least 10% of benign ductal epithelial cells.
  • Compare the success rate of obtaining adequate ductal epithelial cells by random periareolar fine needle aspiration (FNA) and ductal lavage in these patients before vs after 12 months of a prevention intervention.
  • Assess pain associated with FNA and ductal lavage in these women.
  • Correlate, if possible, serum proteomics pattern with cytologic assessment and mammographic density at baseline and at 12 months in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral celecoxib twice daily. Treatment continues for 12 months in the absence of clinical evidence of cancer confirmed by biopsy or unacceptable toxicity.

Patients are assessed at baseline and at 12 months for mammographic breast density, serum hormone levels, and serum IGF-1/IGFBP-3. Patients undergo ductal lavage or fine needle aspiration for assessment of supernatant proteomics and breast biomarkers.

Patients are followed at 2 weeks and then annually for 5 years.

PROJECTED ACCRUAL: A total of 110 patients will be accrued for this study within 10-14 months.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes


  • Increased risk for breast cancer on the basis of at least 1 of the following criteria:

    • Five-year Gail risk at least 1.7% or a calculated risk at least 5 times the average for age group

      • 20-29 years old - calculated 5-year Gail risk is at least 0.1%
      • 30-39 years old - calculated 5-year Gail risk is at least 1.0%
      • 40 and over - calculated 5-year Gail risk is at least 1.7%
    • Known BRCA1/BRCA2 mutation carrier
    • Family history consistent with hereditary breast cancer, as defined by any of the following circumstances:

      • At least 4 relatives with breast cancer at any age
      • At least 2 first-degree relatives diagnosed with breast cancer at age 50 or younger
      • Breast and ovarian cancer diagnosed in the same relative
      • At least 2 occurrences of breast cancer and 1 occurrence of ovarian cancer at any age in the same family
    • Prior biopsy exhibiting atypical hyperplasia, lobular cancer in situ, ductal carcinoma in situ (DCIS)*, or invasive cancer** NOTE: *If DCIS or T1a or T1b disease was found, at least 2 months must have elapsed since prior surgery and/or radiotherapy to the involved breast

NOTE: **Prior invasive cancer (T1c, T2, or T3) must have been diagnosed at least 2 years before study and be estrogen receptor-negative, node negative

  • Must have had a random periareolar fine needle aspiration successfully performed within the past 3 months, with at least 1,000 cells on cytology slide and 3 additional slides for biomarker analysis (1 with at least 500 cells for Ki-67 and 2 with at least 100 ductal cells for estrogen receptors and COX-2)
  • Hormone receptor status:

    • Estrogen receptor negative



  • 18 to 55


  • Female

Menopausal status

  • Premenopausal, defined as menstrual periods estimated to occur every 21 to 35 days over the past 6 months

Performance status

  • Not specified

Life expectancy

  • At least 5 years


  • Absolute granulocyte count at least 1,000/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 10 g/dL
  • No bleeding diathesis within the past year


  • Bilirubin no greater than 2.0 mg/dL
  • Albumin at least 3.0 g/dL
  • AST and ALT no greater than 2 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2 times ULN
  • No severe liver disease requiring treatment


  • Creatinine no greater than 1.5 mg/dL


  • No high blood pressure not controlled by medication
  • No history of angina
  • No history of cardiovascular disease
  • No history of deep vein thrombosis


  • No history of pulmonary embolism


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior allergy to sulfa, COX-2 inhibitors, or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • No history of an ulcer requiring treatment
  • No history of ulcerative colitis
  • No inflammatory bowel disease
  • No body mass index > 33
  • No history of diabetes
  • No prior metastatic malignancy of any kind
  • No complications of alcoholism requiring hospitalization
  • No concurrent asthma being treated


Biologic therapy

  • Not specified


  • At least 6 months since prior chemotherapy

Endocrine therapy

  • At least 6 months since prior antihormone therapy (e.g., selective estrogen-receptor modulators or aromatase inhibitors)
  • Anticipated use of oral or IV corticosteroids must be less than 2 weeks per year
  • No change (stop or start) in hormonal therapy within the past 6 months (e.g., estrogen, progesterone, oral contraceptives, or fertility agents)


  • See Disease Characteristics
  • No prior radiotherapy to the contralateral breast involved in the study treatment


  • See Disease Characteristics


  • At least 3 weeks since prior aspirin, rofecoxib, celecoxib, other COX-2 inhibitors, or NSAIDs
  • No concurrent anticoagulants
  • No other concurrent NSAIDs
  • No chronic angiotensin-converting enzyme inhibitors
  • No chronic furosemide*
  • No chronic fluconazole*
  • No chronic lithium NOTE: *Occasional concurrent use allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00056082

United States, Illinois
Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
United States, Kansas
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, United States, 66160-7820
United States, Oklahoma
Oklahoma University Medical Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Kansas Medical Center
National Cancer Institute (NCI)
Study Chair: Carol J. Fabian, MD University of Kansas
  More Information

Responsible Party: Carol Fabian, MD, Director, Breast Cancer Prevention Unit, University of Kansas Medical Center Identifier: NCT00056082     History of Changes
Other Study ID Numbers: KUMC-HSC-8919-02
CDR0000271935 ( Registry Identifier: PDQ (Physician Data Query) )
N01-CN-15135 ( Other Grant/Funding Number: NCI )
Study First Received: March 6, 2003
Last Updated: February 13, 2017
Individual Participant Data  
Plan to Share IPD: No
Plan Description: Global results will be published

Keywords provided by University of Kansas Medical Center:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on April 24, 2017